Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Safety and Efficacy of Palbociclib and Radiation Therapy in Patients With Metastatic Breast Cancer: Initial Results of a Novel Combination.

Chowdhary M, Sen N, Chowdhary A, Usha L, Cobleigh MA, Wang D, Patel KR, Barry PN, Rao RD.

Adv Radiat Oncol. 2019 Apr 3;4(3):453-457. doi: 10.1016/j.adro.2019.03.011. eCollection 2019 Jul-Sep.

2.

Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.

Turturro SB, Najor MS, Yung T, Portt L, Malarkey CS, Abukhdeir AM, Cobleigh MA.

Breast Cancer Res Treat. 2019 Sep;177(2):325-333. doi: 10.1007/s10549-019-05320-x. Epub 2019 Jun 17.

PMID:
31209687
3.

Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient.

Njoroge SW, Burgess KR, Cobleigh MA, Alnajar HH, Gattuso P, Usha L.

Breast Cancer Res Treat. 2017 Nov;166(1):315-319. doi: 10.1007/s10549-017-4393-3. Epub 2017 Jul 12.

PMID:
28702897
4.

Cardiovascular Monitoring With Trastuzumab Therapy: How Frequent Is Too Frequent?

Brann AM, Cobleigh MA, Okwuosa TM.

JAMA Oncol. 2016 Sep 1;2(9):1123-4. doi: 10.1001/jamaoncol.2016.1288. No abstract available.

PMID:
27280310
5.

Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin.

Turturro SB, Najor MS, Ruby CE, Cobleigh MA, Abukhdeir AM.

Breast Cancer Res Treat. 2016 Feb;156(1):33-43. doi: 10.1007/s10549-016-3729-8. Epub 2016 Feb 25.

6.

Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.

Siziopikou KP, Anderson SJ, Cobleigh MA, Julian TB, Arthur DW, Zheng P, Mamounas EP, Pajon ER, Behrens RJ, Eakle JF, Leasure NC, Atkins JN, Polikoff JA, Seay TE, McCaskill-Stevens WJ, Rabinovitch R, Costantino JP, Wolmark N.

Breast Cancer Res Treat. 2013 Nov;142(2):415-21. doi: 10.1007/s10549-013-2755-z. Epub 2013 Nov 8.

7.

Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial.

Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW Jr, Sparano JA, Davidson NE, Badve SS.

Clin Cancer Res. 2013 Mar 1;19(5):1281-9. doi: 10.1158/1078-0432.CCR-12-3029. Epub 2013 Jan 22.

8.

A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice.

Cobleigh MA, Wei X, Robek MD.

J Virol. 2013 Mar;87(5):2969-73. doi: 10.1128/JVI.02111-12. Epub 2012 Dec 26.

9.

Protective and pathological properties of IL-22 in liver disease: implications for viral hepatitis.

Cobleigh MA, Robek MD.

Am J Pathol. 2013 Jan;182(1):21-8. doi: 10.1016/j.ajpath.2012.08.043. Epub 2012 Nov 14. Review.

10.

Adjuvant endocrine therapy for breast cancer.

Rao RD, Cobleigh MA.

Oncology (Williston Park). 2012 Jun;26(6):541-7, 550, 552 passim. Review.

11.

Introduction.

DeMare LE, Cobleigh MA.

Yale J Biol Med. 2012 Mar;85(1):1-2. No abstract available.

12.

The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate.

Cobleigh MA, Bradfield C, Liu Y, Mehta A, Robek MD.

J Virol. 2012 Apr;86(8):4253-61. doi: 10.1128/JVI.05991-11. Epub 2012 Feb 15.

13.

A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus.

Zhang Y, Cobleigh MA, Lian JQ, Huang CX, Booth CJ, Bai XF, Robek MD.

Gastroenterology. 2011 Nov;141(5):1897-906. doi: 10.1053/j.gastro.2011.06.051. Epub 2011 Jun 25.

14.

Other options in the treatment of advanced breast cancer.

Cobleigh MA.

Semin Oncol. 2011 Jun;38 Suppl 2:S11-6. doi: 10.1053/j.seminoncol.2011.04.005. Review.

PMID:
21600380
15.

Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer.

Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H.

Clin Cancer Res. 2011 Jan 15;17(2):372-81. doi: 10.1158/1078-0432.CCR-10-1791. Epub 2011 Jan 11.

16.

Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group.

Rao RD, Cobleigh MA, Gray R, Graham ML 2nd, Norton L, Martino S, Budd GT, Ingle JN, Wood WC.

Med Oncol. 2011 Dec;28 Suppl 1:S39-47. doi: 10.1007/s12032-010-9682-1. Epub 2010 Sep 28.

17.

A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.

Cobleigh MA, Buonocore L, Uprichard SL, Rose JK, Robek MD.

J Virol. 2010 Aug;84(15):7513-22. doi: 10.1128/JVI.00200-10. Epub 2010 May 26.

18.

ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast.

Taylor ME, Haffty BG, Rabinovitch R, Arthur DW, Halberg FE, Strom EA, White JR, Cobleigh MA, Edge SB.

Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):997-1002. doi: 10.1016/j.ijrobp.2008.10.080. Review.

PMID:
19251087
19.

Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer.

Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP.

Breast Cancer Res Treat. 2009 May;115(1):115-21. doi: 10.1007/s10549-008-0055-9. Epub 2008 May 22.

PMID:
18496750
20.

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.

Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD.

J Clin Oncol. 2008 Apr 10;26(11):1810-6. doi: 10.1200/JCO.2007.14.5375. Epub 2008 Mar 17.

PMID:
18347007
21.

Targeting metastatic and advanced breast cancer.

Moore S, Cobleigh MA.

Semin Oncol Nurs. 2007 Feb;23(1):37-45. Review.

PMID:
17303515
23.

Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes.

Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu ML, Borchik R, Mosquera JM, Walker MG, Shak S.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8623-31.

24.

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.

Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ.

Clin Breast Cancer. 2005 Aug;6(3):240-6.

PMID:
16137435
25.

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS.

J Clin Oncol. 2005 Feb 1;23(4):792-9.

PMID:
15681523
26.

Determination of factors associated with hospitalization in breast cancer survivors.

Oleske DM, Cobleigh MA, Phillips M, Nachman KL.

Oncol Nurs Forum. 2004 Nov 16;31(6):1081-8.

PMID:
15547631
27.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR.

J Clin Oncol. 2005 Jan 20;23(3):619-29. Epub 2004 Nov 15. Review.

PMID:
15545664
28.

A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer.

Miller KD, Saphner TJ, Waterhouse DM, Chen TT, Rush-Taylor A, Sparano JA, Wolff AC, Cobleigh MA, Galbraith S, Sledge GW.

Clin Cancer Res. 2004 Mar 15;10(6):1971-5.

29.

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer.

Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD, Vassel A.

Semin Oncol. 2003 Oct;30(5 Suppl 16):117-24.

PMID:
14613032
30.

American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting.

Winer EP, Hudis C, Burstein HJ, Bryant J, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gelber R, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP.

J Clin Oncol. 2003 Jul 1;21(13):2597-9. Epub 2003 May 5. No abstract available.

PMID:
12732612
31.

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.

Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP.

J Clin Oncol. 2002 Aug 1;20(15):3317-27. Review.

PMID:
12149306
32.

Self-reported dietary habits, overall dietary quality and symptomatology of breast cancer survivors: a cross-sectional examination.

Tangney CC, Young JA, Murtaugh MA, Cobleigh MA, Oleske DM.

Breast Cancer Res Treat. 2002 Jan;71(2):113-23.

PMID:
11881909
33.

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M.

J Clin Oncol. 2002 Feb 1;20(3):719-26.

PMID:
11821453
34.

First-line Herceptin monotherapy in metastatic breast cancer.

Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ.

Oncology. 2001;61 Suppl 2:37-42. Review.

PMID:
11694786
35.

First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report.

Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ.

Eur J Cancer. 2001 Jan;37 Suppl 1:25-29.

PMID:
11342197
36.

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.

Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ; Genentech H0650 study investigators.

Eur J Cancer. 2001 Jan;37 Suppl 1:S25-9. Review.

PMID:
11167088
37.

Managing menopausal problems.

Cobleigh MA.

Cancer Treat Res. 2000;103:1-23. Review. No abstract available.

PMID:
10948439
38.

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ.

J Clin Oncol. 1999 Sep;17(9):2639-48.

PMID:
10561337
39.

Hormone replacement therapy and high S phase in breast cancer.

Cobleigh MA, Norlock FE, Oleske DM, Starr A.

JAMA. 1999 Apr 28;281(16):1528-30.

PMID:
10227323
40.

Hormone replacement therapy and nonhormonal control of menopausal symptoms in breast cancer survivors.

Cobleigh MA.

Cancer Treat Res. 1998;94:209-30. Review. No abstract available.

PMID:
9587690
41.

Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.

Bines J, Oleske DM, Cobleigh MA.

J Clin Oncol. 1996 May;14(5):1718-29. Review.

PMID:
8622093
42.

Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer.

Ghalie R, Williams SF, Valentino LA, Feingold J, Korenblit AD, Adler SS, Manson S, Pruett J, Cobleigh MA, Wolter J, Lincoln ST, Hartsell W, Kaizer H.

Biol Blood Marrow Transplant. 1995 Nov;1(1):40-6.

PMID:
9118289
43.

Should multicentric disease be an absolute contraindication to the use of breast-conserving therapy?

Hartsell WF, Recine DC, Griem KL, Cobleigh MA, Witt TR, Murthy AK.

Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):49-53.

PMID:
8083128
44.

Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group.

Cobleigh MA, Berris RF, Bush T, Davidson NE, Robert NJ, Sparano JA, Tormey DC, Wood WC.

JAMA. 1994 Aug 17;272(7):540-5. No abstract available. Erratum in: JAMA 1995 Feb 1;273(5):378.

PMID:
8046809
45.

Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation.

Ghalie R, Richman CM, Adler SS, Cobleigh MA, Korenblit AD, Manson SD, McLeod BC, Taylor SG 4th, Valentino LA, Wolter J, et al.

J Clin Oncol. 1994 Feb;12(2):342-6.

PMID:
8113841
46.

Breast cancer and fenretinide, an analogue of vitamin A.

Cobleigh MA.

Leukemia. 1994;8 Suppl 3:S59-63. Review.

PMID:
7808027
47.

Sequential transplants using mobilized peripheral blood progenitor cells.

Ghalie R, Richman CM, Bender JG, McLeod BC, Lee W, Czyzewski A, Manson S, Cobleigh MA, Reed S, Pierre R, et al.

J Clin Apher. 1994;9(3):176-82.

PMID:
7535760
48.

Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer.

Cobleigh MA, Dowlatshahi K, Deutsch TA, Mehta RG, Moon RC, Minn F, Benson AB 3rd, Rademaker AW, Ashenhurst JB, Wade JL 3rd, et al.

J Clin Oncol. 1993 Mar;11(3):474-7.

PMID:
8445423
49.

Phase II trial of spirogermanium in advanced non-small cell lung cancer. An Illinois Cancer Council Study.

Lad TE, Blough RR, Evrard M, Shevrin DP, Cobleigh MA, Johnson CM, Hange P.

Invest New Drugs. 1989 Jul;7(2-3):223-4.

PMID:
2551841
50.

Phase II trial of fludarabine phosphate in advanced renal cell carcinoma: an Illinois Cancer Council Study.

Shevrin DH, Lad TE, Kilton LJ, Cobleigh MA, Blough RR, Weidner LL, Vogelzang NJ.

Invest New Drugs. 1989 Jul;7(2-3):251-3.

PMID:
2477345

Supplemental Content

Loading ...
Support Center